热景生物股价跌5.06%，浙商证券资管旗下1只基金重仓，持有3.66万股浮亏损失45.57万元

Group 1 - The core viewpoint of the news is that Beijing Hotgen Biotech Co., Ltd. experienced a decline in stock price, with a drop of 5.06% to 233.38 CNY per share, and a total market capitalization of 21.636 billion CNY [1] - The company was established on June 23, 2005, and went public on September 30, 2019, focusing on the research, development, production, and sales of in vitro diagnostic reagents and instruments [1] - The main revenue composition of the company includes diagnostic reagents (81.20%), diagnostic instruments (15.52%), biological raw materials (2.13%), and other supplementary products (1.15%) [1] Group 2 - From the perspective of fund holdings, Zhejiang Securities Asset Management has a fund that heavily invests in Hotgen Biotech, specifically the Zhejiang Huijin Quantitative Selected Mixed Fund (006449), which held 36,600 shares, accounting for 4.96% of the fund's net value [2] - The fund has reported a floating loss of approximately 455,700 CNY as of the latest data [2] - The fund was established on March 25, 2019, with a current size of 104 million CNY, and has achieved a year-to-date return of 45.88% [2]